Last week, Abliva announced the completion of a directed share issue to be approved by the company's upcoming EGM on April 29. The more than 100 million shares were directed at several Swedish and international qualified investors, including Hadean Ventures. At 0.75 SEK an issue, Abliva will raise a total of 80 MSEK, before transaction costs, over two tranches, and the net proceeds are expected to go towards further advancement of the company's clinical assets, mainly KL1333. CEO Ellen Donnelly joined BioStock for a comment on the financing round.
Read the full interview with Ellen Donnelly at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se